Fast-Track Zika Vaccine Development — Is It Possible?

Thomas, Stephen J.; L’Azou, Maïna; Barrett, Alan D.T.; Jackson, Nicholas A.C.

doi:10.1056/nejmp1609300

Cited by 50 publications

(36 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is the hope that rapid development of potent ZIKV therapeutics and vaccines, along with effective vector control, will stop the spread and eliminate large ZIKV epidemics in the near future (Thomas et al, 2016). The recent report of potent neutralizing human antibodies and the mapping of a relevant epitopes is encouraging in light of both treatment and vaccination efforts (Sapparapu et al, 2016).…”

Section: Beyond the Zikv Epidemicsmentioning

confidence: 99%

Advances in Zika Virus Research: Stem Cell Models, Challenges, and Opportunities

2016

View full text Add to dashboard Cite

SummaryThe re-emergence of Zika virus (ZIKV) and its suspected link with various disorders in newborn and adults led the World Health Organization to declare a global health emergency. In response, the stem cell field quickly established platforms for modeling ZIKV exposure using human pluripotent stem cell-derived neural progenitors and brain organoids, fetal tissues and animal models. These efforts provided significant insight into cellular targets, pathogenesis and underlying biological mechanisms of ZIKV infection as well as platforms for drug testing. Here we review the remarkable progress in stem cell-based ZIKV research and discuss current challenges and future opportunities.

show abstract

Section: Beyond the Zikv Epidemicsmentioning

confidence: 99%

Advances in Zika Virus Research: Stem Cell Models, Challenges, and Opportunities

2016

View full text Add to dashboard Cite

show abstract

“…In this case, vaccine supply should be allocated to minimize infections in pregnant women, as perinatal transmission to infants poses the gravest consequences. For this reason, the World Health Organization (WHO) has proposed prioritizing females aged 9–49 followed by males 9–49 for receipt of Zika vaccine (10,11). While vaccinating women in the peak of their fertility years is a clear priority during an outbreak, how to extend vaccination to other women and to men is less clear.…”

Section: Introductionmentioning

confidence: 99%

Evaluating Vaccination Strategies for Zika Virus in the Americas

Durham

Fitzpatrick

Ndeffo-Mbah

et al. 2018

Annals of Internal Medicine

View full text Add to dashboard Cite

Background Mosquito-borne and sexually-transmitted Zika virus infection has become widespread across Central and South America as well as in the Caribbean. Over 30 Zika vaccine candidates are under active development. Objective To quantify the impact of Zika vaccine prioritization of females aged 9–49, followed by males aged 9–49, on the incidence of prenatal Zika infections. Design We developed a compartmental model of Zika transmission between mosquitoes and humans calibrated to empirical estimates of country-specific mosquito density. Mosquitoes were stratified into susceptible, exposed, or infected classes; humans were stratified into susceptible, exposed, infected, recovered, or vaccinated classes. We further incorporated age-specific rates of fertility, Zika sexual transmission, and country-specific demographics. Setting 34 countries or territories in the Americas with documented Zika outbreaks. Target population Males and females aged 9–49. Interventions Age- and gender-targeted immunization using a Zika vaccine with efficacy ranging from 60–90%. Measurements Annual prenatal Zika infections Results For a base-case vaccine efficacy of 75% and vaccination coverage of 90%, immunizing females aged 9–49, the WHO target population, would reduce the incidence of prenatal infections by at least 94%, depending on the country-specific Zika attack rate. In regions where an outbreak is not expected for at least ten years, vaccination of females aged 15–29 is more efficient than vaccinating women over 30 years. Limitations Population-level modeling may not capture all local and neighborhood-level heterogeneity in mosquito abundance or Zika incidence. Conclusions A Zika vaccine of moderate to high efficacy has the potential of virtually eliminating prenatal infections through a combination of direct protection and transmission reduction. Efficiency of age-specific Zika vaccination targeting depends on timing of future outbreaks. Funding National Institutes of Health

show abstract

“…Development pathways and challenges for ZIKV vaccines have recently been reviewed (Marston et al, 2016; Thomas et al, 2016). The experience with other flavivirus vaccines combined with currently available preclinical data for ZIKV vaccines suggest that neutralizing antibodies will likely be important in protection against ZIKV (Abbink et al, 2016; Dowd et al, 2016b; Larocca et al, 2016).…”

Section: Challenges Facing Clinical Development Of Zikv Vaccinesmentioning

confidence: 99%

Prospects for a Zika Virus Vaccine

2017

Self Cite

View full text Add to dashboard Cite

A recent unprecedented outbreak of Zika virus (ZIKV) in the Americas has been associated with microcephaly and other congenital malformations in infants as well as Guillain-Barre syndrome in adults. The development of a safe and effective ZIKV vaccine is therefore an urgent global health priority. Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain. Here we review the current state of ZIKV vaccine development. We discuss different vaccination strategies and, in the context of what has been learnt from other flavivirus vaccines, we highlight challenges facing clinical evaluation of ZIKV vaccine candidates.

show abstract

Fast-Track Zika Vaccine Development — Is It Possible?

Cited by 50 publications

References 4 publications

Advances in Zika Virus Research: Stem Cell Models, Challenges, and Opportunities

Advances in Zika Virus Research: Stem Cell Models, Challenges, and Opportunities

Evaluating Vaccination Strategies for Zika Virus in the Americas

Prospects for a Zika Virus Vaccine

Contact Info

Product

Resources

About